Clinical trial
A Multicenter, Double-blind, Placebo-controlled, Parallel-group, Randomized Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Patients With Post-COVID-19 Asthenia.
NCT05074888 is registered in ClinicalTrials.gov with Materia Medica Holding as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multicenter, Double-blind, Placebo-controlled, Parallel-group, Randomized Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Patients With Post-COVID-19 Asthenia.
- Lead sponsor
- Materia Medica Holding
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- October 15, 2021
- Completion date
- June 8, 2022
- Enrollment
- 676 (actual)
- Sites
- 32
Conditions
As the registry lists them; a condition with its own page is linked.